Media Doctor Canada
Follow us on Twitter








"BP drug wins head-to-head test"

Medical Post

Source: Medical Post

Published: 14 Jun 2022

Category: Pharmaceutical

Rating: (2½ stars)

what they said (Hover the mouse cursor over underlined words for more info)

TORONTO | The angiotensin receptor blocker eprosartan (Teveten) won out in a head-to-head comparison with the calcium channel blocker nitrendipine in hypertensive patients with a history of a cerebrovascular event. Eprosartan reduced secondary strokes and first-time cardiovascular events significantly more than nitrendipine, despite equal blood pressure lowering.

The results confirm the importance of blood pressure lowering in patients following a stroke or transient ischemic attack and suggest angiotensin receptor blockers (ARBs) may play an important role in the management of these patients.

"I think in this population this is one of the clearest demonstrations we've seen of differences in bottom-line effectiveness in the setting of comparable blood pressure lowering," said Dr. Ross Feldman, a cardiologist and professor of physiology and pharmacology at the University of Western Ontario and deputy scientific director of the Robarts Research Institute in London.

The original article can be found at:

The original article can found in the Media Doctor archives.

how did it rate? (more information)

Criteria Rating
Total Score 4 of 9
Availability of Treatment Not Satisfactory (?)
Novelty of Treatment Satisfactory (?)
Disease Mongering Satisfactory (?)
Treatment Options Not Satisfactory (?)
Costs of Treatment Not Satisfactory (?)
Evidence Satisfactory (?)
Quantification of Benefits of Treatment Not Satisfactory (?)
Harms of Treatment Satisfactory (?)
Sources of Information Not Satisfactory (?)
Relies on Press Release Not Applicable
Quantification of Harms of Treatment Not Applicable

what we said (Hover the mouse cursor over underlined words for more info)

This article reports the results of a German and Austrian study called MOSES (morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention). The trial involved 1,352 hypertensive patients who had suffered a cerebrovascular event in the two years prior to the onset of the trial.

The article's main flaw is the lack of any absolute numbers in reporting the treatment benefits, thus denying physicians real insight into the magnitude of the effects. The harms associated with the treatment are mentioned but only briefly and without detail. Additionally, there was no mention of possible conflicts of interest among quoted sources and no attempt at independent corroboration,

public forum

There are currently no comments on this article.

voice your opinion in the forum

  • All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
  • If you provide your email address it will not be displayed to the general public.
  • Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
  • Required fields are marked with an asterisk (*).
Name: *
Comments: *
Copyright © Media Doctor Canada